Journals / Marmara Medical Journal / 2021 / Cilt: 34 - Sayı: 2

Does methylprednisolone affect time to recovery in COVID–19 Pneumonia?

Pages
120–126
Publication Date
2021-05-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although, systemic steroids, started in the subacute period, did not affect the length of hospital stay, they provided a tendency of decrease in the time until the cessation of oxygen supplementation in the subacute period.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Current literature has conflicting results on the role of steroids in the treatment of coronavirus disease 2019 (COVID-19) pneumonia.
📊
Key Findings & Data:Patients and Methods: We retrospectively analyzed the medical records of patients hospitalized for COVID-19 between March and May 2020.
💡
Conclusion & Impact:Conclusion: Although, systemic steroids, started in the subacute period, did not affect the length of hospital stay, they provided a tendency of decrease in the time until the cessation of oxygen supplementation in the subacute period.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:COVID-19 · Steroids · Length of stay

Abstract

Objective: Current literature has conflicting results on the role of steroids in the treatment of coronavirus disease 2019 (COVID-19) pneumonia. This study aims to evaluate the effects of steroids on clinical recovery, duration of hospitalization, and time needed for the cessation of oxygen treatment. Patients and Methods: We retrospectively analyzed the medical records of patients hospitalized for COVID-19 between March and May 2020. Patient age, laboratory parameters, clinical stages, radiologic scores, length of hospital stay, and time needed for the cessation of oxygen supplementation were compared. Results: Thirteen patients were treated with steroids, and 12 controls were included in the analysis. Regarding the laboratory parameters, the groups were similar except for lymphocyte percentage (9.8 ± 3.2, 7.0 ± 2.9; p=0.033), which was higher, and D-dimer levels (0.75 (0.60-1.43), 1.57 (0.91-2.29); p=0.047), which were lower in the steroid group on admission. Steroid treatment provided a tendency of decrease in time to cessation of oxygen supplementation (6.23 ± 3.4 vs 7.67 ± 2.1, p=0.217). Conclusion: Although, systemic steroids, started in the subacute period, did not affect the length of hospital stay, they provided a tendency of decrease in the time until the cessation of oxygen supplementation in the subacute period.

🔖

Cite This Article

KOCAKAYA, D., YILDIZELI, Ş. O., BALCAN, B., ERYUKSEL, E., KARAKURT, S. (2021). Does methylprednisolone affect time to recovery in COVID–19 Pneumonia?. Marmara Medical Journal, Cilt: 34 - Sayı: 2, 120–126. https://ajindex.com/articles/688311

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3
  2. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection 2020;48:155-63. doi: 10.1007/ s15010.020.01401-y Novel Coronavirus Pneumonia Emergency Response Epidemiology Team – The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) Available at: http://weekly.chinacdc.cn/en/ article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51. Accessed: 08.01.2021
  3. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020;8:420-2. doi: 10.1016/ S2213-2600(20)30076-X Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a “Typical” acute respiratory distress syndrome. Am J Respir Crit Care Med 2020;201:1299-300. doi: 10.1164/rccm.202.003.0817LE Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020;191:148-50. doi: 10.1016/j. thromres.2020.04.041 Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med 2020;38:1488-93. doi: 10.1016/j.ajem.2020.04.035 Jiang S, Liu T, Hu Y, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: A meta-analysis. Medicine 2019;98:e16239. doi: 10.1097/ MD.000.000.0000016239 Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 2018;197:757-67. doi: 10.1164/rccm.201.706.1172OC Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Medicine 2006;3:e343. doi: 10.1371/ journal.pmed.0030343 Moreno G, Rodriguez A, Reyes LF, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med 2018;44:1470-82. doi: 10.1007/s00134.018.5332-4 Marik PE. Steroids for sepsis: yes, no or maybe. J Thorac Dis 2018;10(Suppl 9):S1070-S3. doi: 10.21037/jtd.2018.04.35 Biffl WL, Moore FA, Moore EE, Haenel JB, McIntyre RC, Jr., Burch JM. Are corticosteroids salvage therapy for refra